EU/3/14/1255: Orphan designation for the treatment of acute myeloid leukaemia

Volasertib

Table of contents

Overview

On 26 March 2014, orphan designation (EU/3/14/1255) was granted by the European Commission to Boehringer Ingelheim International GmbH, Germany, for volasertib for the treatment of acute myeloid leukaemia.

Key facts

Active substance
Volasertib
Intended use
Treatment of acute myeloid leukaemia
Orphan designation status
Positive
EU designation number
EU/3/14/1255
Date of designation
26/03/2014
Sponsor
Boehringer Ingelheim International GmbH
Binger Strasse 173
D-55216 Ingelheim am Rhein
Germany
Tel. +49 613 2770
Fax +49 613 2720
E-mail: qrpegra.de@boehringer-ingelheim.com

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating